2Lu H, Li Y. Effects of bicyclol on aflatoxin B1 metabolism and hepatotoxicity in rats. Acta Pharmacol Sin 2002;23:942-945.
3Hughes PM, Anthony DC, Ruddin M, Botham MS, Rankine EL, Sablone M, Baumann D, Mir AK, Perry VH. Focal lesions in the rat central nervous system induced by endothelin-1. J Neuropathol Exp Neurol 2003;62:1276-1286.
4Erdem M, Erctem A, Erdem O, Yildirim G, Memis L,Himmetoglu O. Immunohistochemical localization of endothelin-1 in human placenta from normal and growthrestricted pregnancies. Pediatr Dev Pathol 2003;6:307-313.
5Chauhan BC, LeVatte TL, Jollimore CA, Yu PK, Reitsamer HA, Kelly ME, Yu DY,Tremblay F, Archibald ML. Model of endothelin-l-induced chronic optic neuropathy in rat. Invest Ophthalmol Vis Sci 2004;45:144-152.
6Andrzejewska A, Dlugosz JW. The endothelin-1 receptor antagonists ameliorate histology and ultrastructural alterations in the pancreas and decrease trypsinogen activation in severe taurocholate pancreatitis in rats. Int J Exp Pathol 2003;84:221-229.
7Fratz S, Geiger R, Kresse H, Roemer G, Hennig M, Sebening W,Hess J. Pulmonary blood pressure, not flow, is associated with net endothelin-1 production in the lungs of patients with congenital heart disease and normal pulmonary vascular resistance. J Thorac Cardiovasc Surg 2003;126:1724-1729.
8Byrd VM, Kilkenny DM, Dikov MM, Reich MB, Rocheleau JV,Armistead WJ, Thomas JW, Miller GG. Fibroblast growth factor receptor-1 interacts with the T-cell receptor signalling pathway. Immunol Cell Biol 2003;81:440-450.
9Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA,Rosen JM, Ittmann M, Greenberg NM, Spencer DM. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction,extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res 2003;63:6237-6243.
10Brandlein S, Beyer I, Eck M, Bernhardt W, Hensel F, Muller-Hermelink HK, Vollmers HP. Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1.Cancer Res 2003;63:2052-2061.
5Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010; 69: 211-220 [PMID: 20158939 DOI: 10.1017/S0029665110000030].
6Hickman II, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-419 [PMID: 14960526 DOI: 10.1136/ gut.2003.027581].
7Zeng MD, Fan JG, Lu LG, Li YM, Chen CW, Wang BY, Mao YM. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis 2008; 9: 108-112 [PMID: 18419645 DOI: 10.1111/ j.1751-2980.2008.00331.x].
8Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005; 16: 124-128 [PMID: 16245220].
9Lindor KD, Kowdley KV, Heathcote EI, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-778 [PMID: 14999696 DOI: 1O.1002/hep.20092].
10Mendez-Sanchez N, Gonzalez V, Chavez-Tapia N, Ramos MH, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepato12004; 3: 108-112 [PMID: 15505596].
